Anti-Human IL-13 (Tralokinumab)

Anti-Human IL-13 (Tralokinumab)

Product No.: I-2110

- -
- -
Product No.I-2110
Clone
CAT-354
Target
IL-13
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Isotype
Human IgG4κ
Applications
B
,
ELISA
,
ELISA Cap
,
FA
,
N

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Host Species
Hamster
Expression Host
CHO Cells
FC Effector Activity
Active
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 – 8° C Wet Ice
Additional Applications Reported In Literature ?
B,
ELISA,
ELISA Cap,
FA,
N
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tralokinumab. CAT-354 (Tralokinumab) specifically binds to the type 2 cytokine IL-13.
Background
IL-13 is an important mediator of allergic inflammation and disease1 that plays a role in the regulation of IgE synthesis, induction of adhesion molecules, and chemokine expression2. The functions of IL-13 overlap considerably with those of IL-41. IL-13 induces its effects through a multi-subunit receptor composed of the alpha chain of the IL-4 receptor (IL-4Rα) and an IL-13 binding subunit IL-13Rα1. IL-13 induces many features of allergic lung disease, including airway hyper-responsiveness, goblet cell metaplasia, and mucus hypersecretion, which all contribute to airway obstruction. IL-13 is also associated with the induction of chronic pulmonary eosinophilia and eosinophilic esophagitis3 and plays a key role in the pathogenesis of atopic dermatitis4. Although IL-13 is associated primarily with the induction of airway disease, it also has anti-inflammatory properties1.

CAT-354 (Tralokinumab) was isolated and optimized using antibody display technologies3. Tralokinumab acts as a neutralizing antibody2 that binds specifically and with high affinity to IL- 13, preventing interaction with the IL-13 receptor4. In mice administered human IL-13, tralokinumab blocks human IL-13-induced lung eosinophilia, significantly decreases airway hyper-responsiveness, and inhibits eosinophil recruitment to the esophagus3. Tralokinumab does not affect human IL-13-induced goblet cell metaplasia in mouse lungs. Additionally, phase 3 trials produced inconsistent benefits for the treatment of asthma and clinical evaluation was discontinued for this indication4.

Tralokinumab has been studied and approved for use in atopic dermatitis4.

Antigen Distribution
IL-13 is a cytokine secreted by many cell types but especially T helper type 2 (Th2) cells.
Ligand/Receptor
IL-4Rα, IL13RA1, IL13RA2
NCBI Gene Bank ID
UniProt.org
Research Area
Cell Biology
.
Immunology
.
Inflammatory Disease
.
Allergic Inflammation
.
Pro-Inflammatory Cytokines

References & Citations

1 Wynn, TA. et al. (2003) Annu Rev Immunol. 21: 425
2 Kaur D, Hollins F, Woodman L, et al. Allergy. 61(9):1047-1053. 2006.
3 Blanchard C, Mishra A, Saito-Akei H, et al. Clin Exp Allergy. 35(8):1096-1103. 2005.
4 Duggan S. Drugs. 81(14):1657-1663. 2021.
5 Oh CK, Faggioni R, Jin F, et al. Br J Clin Pharmacol. 69(6):645-55. 2010.
6 Singh D, Kane B, Molfino NA, et al. BMC Pulm Med. 10:3. 2010.
B
Indirect Elisa Protocol
Elisa Sandwich Protocol
FA
N

Certificate of Analysis

Formats Available

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.